They expressed especially high hopes for the NIH vaccine, which protected 100% of volunteers who received it in a small study. To induce an immune response to dengue, certain yellow fever genes were swapped out for dengue genes. But, like Sanofi’s Dengvaxia, the Takeda vaccine appears to produce an unbalanced antibody response, with the highest protection offered against dengue 2. The NIH vaccine, called TV003/TV005, also features weakened versions of live dengue, but three of the four components—dengue 1, 3 and 4—are based on whole dengue viruses. The fourth component is based on a dengue 4 backbone with dengue 2 genes spliced in.

Source: Mint January 29, 2018 07:30 UTC